NCT06992713
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
See at-risk trials from Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 26 words
- Primary completion pushed from Sep 4, 2026 to Jan 31, 2027
- Study completion pushed from Nov 30, 2026 to Apr 30, 2027
- Site details revised at 1 of 4 sites
- Minor Study sites: 3 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 28, 2025 to Jun 18, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and severity of treatment-emergent adverse events
Timeframe: Up to ~ 18 months
Dose Limiting Toxicities(DLT)
Timeframe: Up to ~ 18 months
Maximum Tolerated Dose (MTD)
Timeframe: Up to ~ 18 months
Recommended Phase 2 Dose (RP2D)
Timeframe: Up to ~ 18 months
Secondary (9)
Maximum Observed Concentration(Cmax) of H1710
Time of Maximum Concentration (Tmax)of H1710
Area Under the Concentration (AUC) of H1710
Terminal Half life( t½) of H1710
Clearance (CL) of H1710
Show 4 moreShow less
Objective Response Rate (ORR)
Disease Control Rate(DCR)
Duration of Response (DOR)
Progression Free Survival (PFS)
Arms and interventions
H1710 for InjectionExperimental
Participants receive H1710 for Injection according to the protocol.
Drugs: H1710 for Injection
Sites
4 sites in 1 country